News
CMPS
8.38
-0.48%
-0.04
Cantor Fitzgerald Reiterates Overweight on Compass Pathways
Benzinga · 18h ago
Cantor Fitzgerald Reiterates Overweight on Compass Pathways
Benzinga · 1d ago
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 2d ago
Who's Who In Cannabis: Latest Executive Changes You Should Know About
Decibel Cannabis Company Inc. Named Benjamin Sze as its new CEO. The Benzinga Cannabis Capital Conference gets underway in Florida this week. U.S.-based multi-state cannabis operators have surpassed the $500,000 base salary threshold in 2024. The median CEO salary in the industry is now $511,600.
Benzinga · 4d ago
Weekly Report: what happened at CMPS last week (0408-0412)?
Weekly Report · 5d ago
Weekly Report: what happened at CMPS last week (0401-0405)?
Weekly Report · 04/08 09:02
Atai Life Sciences upgraded at Maxim on Beckley investment
Atai Life Sciences upgraded at Maxim on Beckley investment. The German company recently invested in Beckley Psytech, a private biotech focused on developing short-duration psychedelics. Maxim Group raised its recommendation to Buy from Hold on Atai Life sciences. The company is expected to triples down on short-acting psychedelics with Beckley.
Seeking Alpha · 04/03 14:47
Micron, Iris Energy, Trip.com Group And Other Big Stocks Moving Higher On Monday
Micron Technology, Inc. Shares rose 6.6% to $125.69 on Monday. The Dow Jones fell around 250 points in today's session. Shares of Micron Technology rose sharply after B of A Securities maintained a Buy rating on the stock. Other big stocks recording gains include Doma Holdings and Ouster.
Benzinga · 04/01 17:02
Analysts’ Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)
TipRanks · 04/01 11:21
Compass Pathways Price Target Announced at $30.00/Share by Morgan Stanley
Dow Jones · 04/01 10:59
Compass Pathways Initiated at Overweight by Morgan Stanley
Dow Jones · 04/01 10:59
Morgan Stanley Initiates Coverage On Compass Pathways with Overweight Rating, Announces Price Target of $30
Benzinga · 04/01 10:49
Weekly Report: what happened at CMPS last week (0325-0329)?
Weekly Report · 04/01 09:02
Buy Rating on COMPASS Pathways: COMP360’s Market Potential and Promising TRD Therapy
Morgan Stanley analyst Vikram Purohit has initiated a new Buy rating on COMPASS Pathways (CMPS) The company is developing a drug for treating treatment-resistant depression. The drug has shown strong Phase II data for treating the disorder. The company has a $30 price target for the stock.
TipRanks · 04/01 08:17
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Benzinga's psychedelic headlines roundup includes news from the last two weeks of March 2024. Psychedelic therapy as a form of life and the role of psychedelics in the management of chronic pain are among the topics. A new study shows psilocybin is a prodrug of psilocin. Frank Herbert’s magic mushrooms are available in Canada.
Benzinga · 03/30 12:57
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Clinical-stage psychedelics biotech Atai Life Sciences announced its consolidated financial results for the fourth quarter and full year 2023. The company expects to have $154.2 million in cash by December 31, 2023, down from $273.1 million in 2022. Atai expects to fund operations into 2026.
Benzinga · 03/29 13:20
COMPASS Pathways Leadership Restructure and Board Reshuffle
Compass Pathways (CMPS) announced two resignations from the board. The departures are not due to any disagreements with the company's operations or practices. The board will be restructured to include eight directors in three different classes. George Goldsmith and Ekaterina Malievskaia have announced their resignations.
TipRanks · 03/28 12:12
Compass Pathways Board Chair And Co-Founder George Goldsmith And Co-Founder Ekaterina Malievskaia Step Down From Board Of Directors, Effective March 29, 2024
Compass Pathways plc is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. George Goldsmith and Ekaterina Malievskaia have resigned their seats on the company's board of directors. David Norton, lead independent director on the board, will become interim chair. Compass is running a global search for a permanent board chair.
Benzinga · 03/28 12:09
Weekly Report: what happened at CMPS last week (0318-0322)?
Weekly Report · 03/25 09:02
More
Webull provides a variety of real-time CMPS stock news. You can receive the latest news about Compass Pathways Plc through multiple platforms. This information may help you make smarter investment decisions.
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.